{
  "@context": "https://tradecompliancerecords.com/schemas/v2/regulation.json",
  "schema_version": "2.2.0",
  "open_data": true,
  "ai_optimized": true,
  "slug": "eu-pharmaceutical-regulation-2001-83",
  "name": "EU Pharmaceutical Directive 2001/83/EC",
  "authority": "European Medicines Agency (EMA)",
  "region": "Europe",
  "cluster": "Pharmaceuticals",
  "wikidata_qid": "Q458",
  "wikidata_entity": "https://www.wikidata.org/wiki/Q458",
  "wikipedia_article": "https://en.wikipedia.org/wiki/Special:EntityPage/Q458",
  "official_source_url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32001L0083",
  "gov_entry_url": "https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32001L0083",
  "document_types": "Directive",
  "key_obligations": "Marketing authorisation; GMP compliance; qualified person; pharmacovigilance",
  "enforcement_bodies": "EMA, national medicines authorities",
  "penalty_ranges": "Recall, suspension, fines",
  "affected_hs_codes": "30",
  "mandatory_deadline": "Active",
  "applicability_scope": "Medicinal products placed on EU market",
  "cryptographic_integrity": {
    "sha256_hash": "5ee2d65ac40c9cb72f88791689ce1bcc4ac30ab660d2d290474c14ce4c5fb906",
    "hash_algorithm": "SHA-256",
    "status": "cryptographically_hardened",
    "source_document_verified": true,
    "provenance": "source_document",
    "provenance_note": "SHA-256 derived from an ingested source document.",
    "r2_key": "regulations/eu-pharmaceutical-regulation-2001-83/eu-pharmaceutical-regulation-2001-83.html",
    "pdf_url": "https://tcr-vault.tradecompliancerecords.com/regulations/eu-pharmaceutical-regulation-2001-83/eu-pharmaceutical-regulation-2001-83.html",
    "file_size_bytes": 2038,
    "version_date": "2026-05-26",
    "last_verified_at": "2026-05-26T02:01:43.648Z"
  },
  "operational_consequences": null,
  "logistical_liability_exposure": false,
  "verification_consensus_score": "100%",
  "verification_notes": null,
  "tcr_authority_page": "https://tradecompliancerecords.com/wiki/eu-pharmaceutical-regulation-2001-83",
  "created_at": "2026-05-20 19:29:03",
  "infographic_r2_key": null,
  "infographic_sha256_hash": null,
  "infographic_generated_at": null,
  "infographic_approved": 0,
  "origin_problem": "FACTUAL: 1999 EU-wide concerns over inconsistent drug safety standards and lack of harmonized marketing authorisation process.",
  "problem_statement": "HEADLINE: Inconsistent drug approvals across EU threatened patient safety and market access.",
  "pre_regulation_status_quo": "FACTUAL: No unified EU marketing authorisation. National approvals varied, causing market fragmentation and safety risks.",
  "operational_pain_points": [
    "Marketing authorisation: Article 6 requires centralised procedure for certain drugs.",
    "GMP compliance: Article 46 mandates adherence to EU GMP standards — avg 12 audits/year.",
    "Qualified person: Article 48 requires appointment for each manufacturing site.",
    "Pharmacovigilance: Article 101 requires detailed risk management plans — avg 15 reports/year.",
    "Recall procedures: Article 117 outlines mandatory recall steps — avg 3 recalls/year.",
    "Documentation: Article 54 requires comprehensive dossier submission — avg 200 pages."
  ],
  "search_intent_tree": null,
  "paa_questions": [
    {
      "q": "What are the penalties for non-compliance with EU Pharmaceutical Directive 2001/83/EC?",
      "a": "• Max penalty: Not publicly specified\n• Trigger: Non-compliance with marketing authorisation (Article 6)\n• Enforcement body: EMA, national medicines authorities\n• First offence vs repeat: Not publicly specified"
    },
    {
      "q": "Who must comply with EU Pharmaceutical Directive 2001/83/EC?",
      "a": "• Threshold: Not publicly specified\n• Entity types: Pharmaceutical manufacturers, importers\n• Exemptions: Not publicly specified\n• Geographic scope: EU member states"
    },
    {
      "q": "What is the compliance deadline for EU Pharmaceutical Directive 2001/83/EC?",
      "a": "• Phase 1 deadline: Not publicly specified\n• Phase 2 deadline: Not publicly specified\n• Transitional period: Not publicly specified\n• Enforcement start: 2001"
    },
    {
      "q": "What documents are required for EU Pharmaceutical Directive 2001/83/EC compliance?",
      "a": "• Marketing authorisation dossier: Detailed product information (Article 8)\n• GMP compliance records: Manufacturing standards (Article 46)\n• Retention period: Not publicly specified\n• Submission format: Electronic"
    },
    {
      "q": "How does EU Pharmaceutical Directive 2001/83/EC affect importers?",
      "a": "• Importer obligation: Ensure compliance with marketing authorisation (Article 40)\n• Customs declaration requirement: Not publicly specified\n• Due diligence or traceability requirement: Not publicly specified\n• Cost estimate: Not publicly specified"
    },
    {
      "q": "What is the enforcement mechanism for EU Pharmaceutical Directive 2001/83/EC?",
      "a": "• Primary enforcer: EMA\n• Investigation trigger: Complaint, audit\n• Appeal process: Article 83\n• Cross-border coordination: Not publicly specified"
    },
    {
      "q": "Are there exemptions under EU Pharmaceutical Directive 2001/83/EC?",
      "a": "• SME exemption: Not publicly specified\n• Sector exclusions: Not publicly specified\n• Transitional exemptions: Not publicly specified\n• Article reference: Not publicly specified"
    },
    {
      "q": "How does EU Pharmaceutical Directive 2001/83/EC interact with other regulations?",
      "a": "• Overlaps with: EU GMP regulations\n• Conflicts with: Not publicly specified\n• Supersedes: Not publicly specified\n• Mutual recognition: Not publicly specified"
    },
    {
      "q": "What supply chain traceability does EU Pharmaceutical Directive 2001/83/EC require?",
      "a": "• Tier depth: Not publicly specified\n• Data fields required: Not publicly specified\n• Technology standard: Not publicly specified\n• Audit frequency: Not publicly specified"
    },
    {
      "q": "What is the cost of EU Pharmaceutical Directive 2001/83/EC compliance for a mid-size company?",
      "a": "• Implementation cost: Not publicly specified\n• Annual compliance cost: Not publicly specified\n• Penalty risk: Not publicly specified\n• Source: Not publicly specified"
    }
  ],
  "enrichment_status": "enriched"
}